explore -WSS

explore

author：fashion 2025-09-30 20:47:57 - browse：35

Akero Therapeutics said Tuesday that an experimental medicine failed to show a significant benefit for patients with cirrhosis caused by NASH, the most advanced and life-threatening stage of the fatty liver disease.

While the study’s primary goal of improving liver fibrosis, or scarring, was not achieved, the Akero drug, called efruxifermin, outperformed placebo by 10 percentage points. The drug also resolved NASH symptoms, including reductions in liver fat and inflammation, and improved other markers of the disease.

“These are the best data reported to date for any NASH drug in this patient population,” said Kitty Yale, Akero’s chief development officer. “We missed the primary endpoint. We understand that, but there’s actually a lot of hope when you look at the totality of the data.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： Study says nonprofit hospitals fall short in charity care spending

WSS

New guidelines on severe brain injury complicate already difficult decisions

With FDA staff opposed to Sarepta therapy, top official intervened

There's no autism epidemic. It's an autism diagnosis epidemic

Adam's Biotech Scorecard: A closer look at Viking Therapeutics, PDS Biotech

FDA grants conditional OK to Sarepta’s gene therapy for Duchenne

Colonoscopy at 40? Study finds a possible benefit

knowledge

explore

focus

Guidelines to prevent youth baseball injuries need more muscle

Decaf coffee targeted by food safety group under obscure FDA rule

What does generative AI mean for health care? We asked experts

In areas with more Black doctors, Black people live longer

Duchenne breakthrough therapy leaves behind pioneering families

Readout Newsletter: Blackstone Life Sciences, Merck, Bluebird Bio

After affirmative action ruling, medical educators look to 'holistic review'

Gene therapy has helped boys walk. Can scientists keep it that way?

United colonoscopy coverage change 'may cost lives,' doctors say

Adam's Biotech Scorecard: A closer look at Viking Therapeutics, PDS Biotech

hotspot

Donor acceptance rates hint at racial, gender bias in heart transplants: study

Abortion pill case raises question: who can sue the FDA?

Colonoscopy at 40? Study finds a possible benefit

What is the Wagner Group? The 'brutal' Russian military unit in Ukraine

Cloning humans is technically possible. It's curious no one has tried

The battle over the Brookhaven Landfill on Long Island

hotspot

entertainment

focus

leisure time